MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phas…
Biotechnology
CH, Zug [HQ]
MLTX/Financial Reporting
Income Statements
4 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | |
|
EPS
|
-0.01 | -6.84 | -2.20 | -0.73 | |
| Diluted in mil. | -0.01 | -6.84 | -2.20 | -0.73 | |
|
Profit
|
- - | - - | - - | - - | |
| Gross Margin | - - | - - | - - | - - | |
| Pre Tax | - - | -53.00 | -64.00 | -43.00 | |
| Profit Margin | - - | - - | - - | - - | |
| ETR | - - | -0.01 | -0.06 | -0.21 | |
| Net | - - | -53.00 | -64.00 | -36.00 | |
| Profit Margin | - - | - - | - - | - - | |
| EBITDA | - - | -53.00 | -65.00 | -54.00 | |
| EBITDA Margin | - - | - - | - - | - - | |
| Operating Income | - - | -53.00 | -65.00 | -54.00 | |
| Operating Margin | - - | - - | - - | - - | |
| Interest Income | - - | - - | - - | - - | |
| Loss | - - | -53.00 | -65.00 | -54.00 | |
| Cost of Revenue | - - | - - | - - | - - | |
|
Operating Expenses
|
- - | -53.00 | -65.00 | -54.00 | |
| R&D | - - | -35.00 | -42.00 | -31.00 | |
| G&A | - - | -21.00 | -23.00 | -22.00 | |
| SG&A | - - | -18.00 | -23.00 | -22.00 | |
| S&M | - - | -18.00 | - - | -22,298.00 | |
| Depreciation and Amortization | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | - - | - - | |
| Other Expenses | - - | - - | - - | -10.00 | |
|
WA Shares Outstanding
|
14.00 | 7.00 | 29.00 | 49.00 | |
| Diluted | 14.00 | 7.00 | 29.00 | 49.00 |